Routine adjuvant use of bisphosphonates in breast cancer Arguments in favour and against

Critical Reviews in Oncology/Hematology

Volumn 74, Issue SUPPL. 1, 2010, Pages

  Diel, Ingo ^a   Aebi, Stefan ^b  

^a Institute for Gynecological Oncology   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; LETROZOLE; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG SAFETY; HUMAN; JAW OSTEONECROSIS; REVIEW; VISCERAL METASTASIS;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES;

EID: 77952309508     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(10)70005-6     Document Type: Review

References (21)

1. Zheng Y, Zhou H, Fong-Yee C, et al. Bone resorption increases tumor growth in a mouse model of osteosclerotic breast cancer metastasis. Clin Exp Metastasis 2008, 25:559-567.
2. Zheng Y, Zhou H, Modzelewski JR, et al. Accelerated bone resorption due to dietary calcium deficiency promotes breast cancer tumor growth in bone. Cancer Res 2007, 67:9542-9548.
3. Zheng Y, Zhou H, Brennan K, et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007, 40:471-478.
4. Krempien B, Diel I, Jöckle-Kretz B, et al. The Walker Carcinosarcoma 256 model for the development of bone metastases. Influence of skeletal metabolism on the development of bone metastases. Verh Dtsch Ges Path 1984, 68:211-216.
5. Senaratne SG, Prianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000, 82:1459-1468.
6. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells; evidence for synergy with paclitaxel. Br J Cancer 2001, 84:1126-1134.
7. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000, 60:2949-2954.
8. Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P Antitumor effects of clinical dosis regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99:322-330.
9. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363.
10. Diel IJ Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol 2001, 28(11):75-80.
11. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow - a long term follow-up. Ann Oncol 2008, 19:2007-2011.
12. Saarto T, Blomqvist C, Virkkunen P, Elomaa I Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001, 19:10-17.
13. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
14. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219-3224.
15. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
16. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
17. Eidtmann H, Bundred NJ, DeBoer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res 2009, 69(Suppl 2):74S. [abstract 44].
18. Winter MC, Thorpe HC, Burkinshaw R The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumour activity in breast cancer. Cancer Res 2009, 69(Suppl 2):5101. [abstract].
19. Pavlakis N, Schmidt R, Stockler M Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005, CD003474.
20. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008, 112:1001-1010.
21. Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. J Clin Oncol 2008, 26(Suppl 15S, Pt II):1006S.